Previous studies have shown that ALK inhibition synergizes with chemotherapy or CDK4 inhibition in preclinical models of neuroblastoma (Krytska et al., 2016; Wood et al., 2016), and a clinical trial (NCT02780128) for testing the combination of ceritinib and ribociclib in ALK-mutant neuroblastoma patients is ongoing. This evidence concerns the gene CDK4 and neuroblastoma.